CV outcomes in patients with type 2 diabetes, canagliflozin, cardiorespiratory fitness, the value of randomized trials, and the most important paper of 2018 are reviewed in this week's podcast.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
